Publications du CNR en 2017

Allerberger, F., Cambau, E. and Lange, C. (2017). Joint efforts urgently needed at times of emerging tuberculosis drug resistance. Clinical Microbiology and Infection 23, 129–130,
Andre, E., Goeminne, L., Cabibbe, A., Beckert, P., Mukadi, B. K., Mathys, V., Gagneux, S., Niemann, S., Ingen, J. V. and Cambau, E. (2017). Consensus numbering system for the rifampicin resistance-associated rpoB gene mutations in pathogenic mycobacteria. Clinical Microbiology and Infection 23, 167–172,
Appelgren, A., Morquin, D., Dufour, S., Le Moing, V., Reynes, J., Lotthé, A., Parer, S., Corbeau, C., Aubry, A., Sougakoff, W., Solassol, J., Bonzon, L., Dumont, Y. and Godreuil, S. (2017). Investigation of pre-XDR Beijing Mycobacterium tuberculosis transmission to a healthcare worker in France, 2016. Journal of Hospital Infection,
Aubry, A., Mougari, F., Reibel, F. and Cambau, E. (2017). Mycobacterium marinum. Microbiology Spectrum 5,
Bouchet, F., Martin, B., Aubry, A., Veziris, N., Lavigne, J.-P. and Sotto, A. (2017). Should single antibiotic therapy be avoided for nontuberculous mycobacteria? Médecine et Maladies Infectieuses,
Brossier, F. and Sougakoff, W. (2017). Molecular detection methods of resistance to antituberculosis drugs in Mycobacterium tuberculosis. Médecine et Maladies Infectieuses 47, 340–348,
Brossier, F., Pham, A., Bernard, C., Aubry, A., Jarlier, V., Veziris, N., Sougakoff, W. and CNR-MyRMA, O. B. of T. (2017). Molecular Investigation of Resistance to Second-Line Injectable Drugs in Multidrug-Resistant Clinical Isolates of Mycobacterium tuberculosis in France. Antimicrob Agents Chemother 61, e01299-16,
Delafont, V., Samba-Louaka, A., Cambau, E., Bouchon, D., Moulin, L. and Héchard, Y. (2017). Mycobacterium llatzerense, a waterborne Mycobacterium, that resists phagocytosis by Acanthamoeba castellanii. Scientific Reports 7, 46270,
Fournier, A., Bernard, C., Sougakoff, W., Quelet, S., Antoun, F., Charlois-Ou, C., Dormant, I., Dufour, M.-O., Hocine, N., Jarlier, V. and Veziris, N. (2017). Neither genotyping nor contact tracing allow correct understanding of multidrug-resistant tuberculosis transmission. European Respiratory Journal 50, 1700891,
Guglielmetti, L., Jaspard, M., Dû, D. L., Lachâtre, M., Marigot-Outtandy, D., Bernard, C., Veziris, N., Robert, J., Yazdanpanah, Y., Caumes, E. and Fréchet-Jachym, M. (2017). Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis. European Respiratory Journal 49, 1601799,
Guglielmetti, L., Hewison, C., Avaliani, Z., Hughes, J., Kiria, N., Lomtadze, N., Ndjeka, N., Setkina, S., Shabangu, A., Sikhondze, W., Skrahina, A., Veziris, N. and Furin, J. (2017). Examples of bedaquiline introduction for the management of multidrug-resistant tuberculosis in five countries. The International Journal of Tuberculosis and Lung Disease 21, 167–174,
Jaspard, M., Elefant-Amoura, E., Melonio, I., de Montgolfier, I., Veziris, N. and Caumes, E. (2017). Bedaquiline and Linezolid for Extensively Drug-Resistant Tuberculosis in Pregnant Woman. Emerging Infect Dis 23,
Leyer, C., Gregorowicz, G., Mougari, F., Raskine, L., Cambau, E. and Briel, D. de (2017). Comparison of Saramis 4.12 and IVD 3.0 Vitek MS Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry for Identification of Mycobacteria from Solid and Liquid Culture Media. Journal of Clinical Microbiology 55, 2045–2054,
Maitre, T., Aubry, A. and Veziris, N. (2017). Molecular Drug-Susceptibility Test for Tuberculosis. New England Journal of Medicine 377, 2403–2404,
Maitre, T., Petitjean, G., Chauffour, A., Bernard, C., El Helali, N., Jarlier, V., Reibel, F., Chavanet, P., Aubry, A. and Veziris, N. (2017). Are moxifloxacin and levofloxacin equally effective to treat XDR tuberculosis? J Antimicrob Chemother 72, 2326–2333,
Maitre, T., Aubry, A., Jarlier, V., Robert, J., Veziris, N., Bernard, C., Sougakoff, W., Brossier, F., Cambau, E., Mougari, F. and Raskine, L. (2017). Multidrug and extensively drug-resistant tuberculosis. Médecine et Maladies Infectieuses 47, 3–10,
Mazoyer, A., Ycart, B. and Veziris, N. (2017). Correction: Unbiased Estimation of Mutation Rates under Fluctuating Final Counts. PLOS ONE 12, e0173143,
Mougari, F., Loiseau, J., Veziris, N., Bernard, C., Bercot, B., Sougakoff, W., Jarlier, V., Raskine, L. and Cambau, E. (2017). Evaluation of the new GenoType NTM-DR kit for the molecular detection of antimicrobial resistance in non-tuberculous mycobacteria. J Antimicrob Chemother 72, 1669–1677,
Mougari, F., Bouziane, F., Crockett, F., Nessar, R., Chau, F., Veziris, N., Sapriel, G., Raskine, L. and Cambau, E. (2017). Selection of Resistance to Clarithromycin in Mycobacterium abscessus Subspecies. Antimicrob Agents Chemother 61, e00943-16,
Schön, T., Miotto, P., Köser, C. U., Viveiros, M., Böttger, E. and Cambau, E. (2017). Mycobacterium tuberculosis drug-resistance testing: challenges, recent developments and perspectives. Clinical Microbiology and Infection 23, 154–160,
Veziris, N., Bernard, C., Guglielmetti, L., Du, D. L., Marigot-Outtandy, D., Jaspard, M., Caumes, E., Lerat, I., Rioux, C., Yazdanpanah, Y., Tiotiu, A., Lemaitre, N., Brossier, F., Jarlier, V., Robert, J., Sougakoff, W. and Aubry, A. (2017). Rapid emergence of Mycobacterium tuberculosis bedaquiline resistance: lessons to avoid repeating past errors. European Respiratory Journal 49, 1601719,
Wyplosz, B., Mougari, F., Rawi, M. A., Baillon, C., Marigot-Outtandy, D., Dû, D. L., Jachym, M., Hervé, V., Raskine, L. and Cambau, E. (2017). Visualizing viable Mycobacterium tuberculosis in sputum to monitor isolation measures. Journal of Infection 74, 207–210,